Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03645928
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT03645928 ↗
- Terminated
- Iovance Biotherapeutics, Inc.
- Focused
We haven't built an HCP commentary report on NCT03645928 (lifileucel, LN-145 and 10 more in Metastatic Melanoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03645928 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Metastatic Melanoma; Squamous Cell Carcinoma of the Head and Neck; Non-small Cell Lung Cancer
- Interventions
- Lifileucel; LN-145; Pembrolizumab; LN-145-S1; Ipilimumab; Nivolumab; Nivolumab-relatlimab; Cisplatin; Carboplatin; Paclitaxel; Nab paclitaxel; Pemetrexed
- Arms
- Cohort 1A · Experimental
- Cohort 1B · Experimental
- Cohort 1C · Experimental
- Cohort 2A · Experimental
- Cohort 3A · Experimental
- Cohort 3B · Experimental
- Cohort 3C · Experimental
- Cohort 3D · Experimental
- Cohort 3E · Experimental
- Cohort 1D · Experimental
- Enrollment
- 225
- Primary outcomes
- Objective Response Rate
- Safety Profile Measured by Grade ≥3 TEAEs
- Percentage of patients for whom lifileucel is successfully manufactured and meets release specification
- Sponsor
- Iovance Biotherapeutics, Inc.
- Start
- May 7, 2019
- Primary completion
- Feb 20, 2026
- Results posted
- No
- Registry record
- NCT03645928 · updated May 15, 2026
Publications
linked from the registry- Hensel J, Metts J, Gupta A, Ladle BH, Pilon-Thomas S, Mullinax J. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. Cancer J. 2022 Jul-Aug 01;28(4):322-327. doi: 10.1097/PPO.0000000000000603. PubMed 35880942